Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 14Ovarian Neoplasms 12Triple Negative Breast Neoplasms 6Fallopian Tube Neoplasms 6Neoplasms 5Stomach Neoplasms 4Pancreatic Neoplasms 4Neoplasm Metastasis 4Lymphoma 3Lung Neoplasms 3Colonic Neoplasms 3Breast Neoplasms, Male 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Melanoma 2Medulloblastoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelomonocytic, Acute 2Leukemia, Myeloid, Acute 2Hereditary Breast and Ovarian Cancer Syndrome 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Astrocytoma 2Zollinger-Ellison Syndrome 1Vipoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Testicular Neoplasms 1Stage IV Fallopian Tube Cancer AJCC v6 and v7 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11Bortezomib 8Filgrastim 7fludarabine 6Vorinostat 6Etoposide 6tanespimycin 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Doxorubicin 5Busulfan 5aldesleukin 4Vincristine 4Tacrolimus 4Paclitaxel 4Lenalidomide 4Gemcitabine 4sargramostim 3nelarabine 3Whole-Body Irradiation 3Topotecan 3Leucovorin 3Irinotecan 3Fluorouracil 3Everolimus 3Dexamethasone 3Dasatinib 3Cytarabine 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × veliparib × Clear all
NCT01139970 2025-11-20

Veliparib and Temozolomide in Treating Patients With Acute Leukemia

National Cancer Institute (NCI)

Phase 1 Completed
66 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡